▶Etravirineis predicted to decrease the exposure tobosutinib.
Avoid.rTheoretical
▶Etravirineincreases the anticoagulant effect ofcoumarins.
oTheoretical
▶Etravirineis predicted to decrease the exposure todaclatasvir.
Avoid.oTheoretical
▶Etravirinemoderately decreases the exposure todolutegravir.
Avoid unless given with atazanavir, darunavir, or lopinavir (all
boosted with ritonavir).rStudy
▶Efavirenzis predicted to decrease the exposure toetravirine.
Avoid.rStudy
▶Etravirineis predicted to decrease the exposure toelbasvir.
Avoid.qTheoretical
▶Enzalutamideis predicted to decrease the exposure to
etravirine. Avoid.rTheoretical
▶Etravirineis predicted to decrease the exposure tograzoprevir.
Avoid.nTheoretical
▶HIV-protease inhibitors(tipranavir)decrease the exposure to
etravirine. Avoid.rStudy
▶Etravirineincreases the exposure toHIV-protease inhibitors
(fosamprenavir)(boosted with ritonavir). Refer to specialist
literature.oStudy
▶Etravirinedecreases the exposure tomacrolides
(clarithromycin).rStudy
▶Etravirine(with a boosted protease inhibitor) increases the
exposure tomaraviroc. Avoid or adjust dose.oStudy
▶Mitotaneis predicted to decrease the exposure toetravirine.
Avoid.rTheoretical
▶Nevirapineis predicted to decrease the exposure toetravirine.
Avoid.rStudy
▶Etravirinemoderately decreases the exposure to
phosphodiesterase type-5 inhibitors. Adjust dose.o
Study
▶Rifabutindecreases the exposure toetravirine.oStudy
▶Rifampicinis predicted to decrease the exposure toetravirine.
Avoid.rTheoretical
▶Etravirineis predicted to decrease the exposure torilpivirine.
Avoid.rTheoretical
▶Etravirineis predicted to decrease the exposure tosimeprevir.
Avoid.oStudy
▶St John’s Wortis predicted to decrease the exposure to
etravirine. Avoid.rStudy
Everolimus→seeTABLE 15p. 850 (myelosuppression)
▶Antiarrhythmics(dronedarone)are predicted to increase the
concentration ofeverolimus. Avoid or adjust dose.o
Study
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the
concentration ofeverolimus. Avoid or adjust dose.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the concentration ofeverolimus.
Avoid or adjust dose.oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the concentration ofeverolimus. Avoid.
rStudy
▶Aprepitantis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy
▶Bosentanis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofeverolimus. Avoid or adjust
dose.oStudy
▶Ceritinibis predicted to increase the exposure toeverolimus.
oTheoretical→Also seeTABLE 15p. 850
▶Ciclosporinmoderately increases the exposure toeverolimus.
Avoid or adjust dose.rStudy
▶Cobicistatis predicted to increase the concentration of
everolimus. Avoid.rStudy
▶Crizotinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Efavirenzis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶Eliglustatis predicted to increase the exposure toeverolimus.
Adjust dose.oStudy
▶Enzalutamideis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶Grapefruit juiceis predicted to increase the exposure to
everolimus. Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to increase the
concentration ofeverolimus. Avoid.rStudy
▶Idelalisibis predicted to increase the concentration of
everolimus. Avoid.rStudy→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Lapatinibis predicted to increase the exposure toeverolimus.
oTheoretical
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
everolimus. Public Health England advises avoid (refer to
Green Book).rTheoretical
▶Everolimusis predicted to increase the exposure tolomitapide.
Separate administration by 12 hours.oTheoretical
▶Lumacaftoris predicted to decrease the exposure to
everolimus. Avoid.rTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
concentration ofeverolimus. Avoid.rStudy
▶Macrolides(erythromycin)are predicted to increase the
concentration ofeverolimus. Avoid or adjust dose.o
Study
▶Mirabegronis predicted to increase the exposure to
everolimus.nTheoretical
▶Mitotaneis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy→Also see
TABLE 15p. 850
▶Netupitantis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy
▶Nevirapineis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶Nilotinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Palbociclibis predicted to increase the exposure toeverolimus.
Adjust dose.oTheoretical
▶Pitolisantis predicted to decrease the exposure toeverolimus.
Avoid.rTheoretical
▶Ribociclibis predicted to increase the exposure toeverolimus.
Use with caution and adjust dose.oTheoretical
▶Rifampicinis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶St John’sWortis predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶Velpatasviris predicted to increase the exposure to
everolimus.rTheoretical
Exemestane
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)moderately decrease the exposure to
exemestane.oStudy
▶Enzalutamidemoderately decreases the exposure to
exemestane.oStudy
▶Mitotanemoderately decreases the exposure toexemestane.
oStudy
▶Rifampicinmoderately decreases the exposure toexemestane.
oStudy
▶St John’sWortis predicted to decrease the exposure to
exemestane.oTheoretical
Exenatide→seeTABLE 14p. 850 (antidiabetic drugs)
SEPARATION OF ADMINISTRATIONWith standard-release
exenatide: some orally administered drugs should be taken at
least 1 hour before, or 4 hours after, exenatide injection.
Ezetimibe
▶Ciclosporinmoderately increases the exposure toezetimibe
andezetimibeslightly increases the exposure tociclosporin.
oStudy
▶Fibratesare predicted to increase the risk of gallstones when
given withezetimibe.rTheoretical
▶Ezetimibepotentially increases the risk of rhabdomyolysis
when given withstatins.rAnecdotal
Famotidine→see H 2 receptor antagonistsBNFC 2018 – 2019 Etravirine—Famotidine 921
Interactions|Appendix 1A1